It has been reported that polymerized human albumin (poly-HSA) reacts with certain sera from patients with hepatitis (5, 8, 9) . The results were obtained by gel diffusion and passive hemagglutination tests. The reacting agent(s) was interpreted to be antibodies, although they were thought to be of different immunoglobulin classes. Recently, Imai et al. (6) and Neurath (11) found that hepatitis B surface antigen (HBsAg), predominantly from sera positive for hepatitis B "e" antigen (HBeAg), reacted with poly-HSA.
It was considered to be of interest to try to confirm, with sensitive methods, the findings of anti-poly-HSA in patients with hepatitis, especially in light of the reports of reaction between poly-HSA and HBsAg. To further study the interaction between HBsAg and poly-HSA, a solid-phase radioimmunoassay was developed, using microtiter plates coated with poly-HSA. The HBeAg and anti-HBe assays. HBeAg and antiHBe were assayed by a solid-phase radioimmunoassay (10) .
Passive hemagglutination tests. Unfixed human group 0 erythrocytes coated with poly-HSA, monomeric HSA, or bovine serum albumin plus uncoated cells were obtained from D. De Souza, Electro-Nucleonics Laboratories. Serial dilutions of sera with or without HBsAg were tested for their abilities to agglutinate the albumin-coated erythrocytes.
RESULTS
Anti-poly-HSA. Anti-poly-HSA could not be detected in any ofthe sera tested by any method: 12 sera from chronic carriers of HBsAg tested by immunoelectroosmophoresis, 25 sera from chronic HBsAg carriers and serial bleedings from one chimpanzee infected with hepatitis A and one infected with non-A, non-B hepatitis virus tested by enzyme-linked immunosorbent assay, and 27 sera from chronic HBsAg carriers tested by radioimmunoprecipitation assay.
PAA. (i) Coating of microtiter plates.
Fractionation on a Sephadex G-200 column of the glutaraldehyde-treated HSA solution showed one peak of poly-HSA in the void volume and one peak of monomeric HSA (Fig. 1) .
A portion from each fraction was diluted in coating buffer to contain 50 ,ug of protein per ml and was used for coating the wells of a microtiter plate. A 1/50 dilution of a serum containing HBsAg was used to investigate the ability of the HSA from the different fractions to bind HBsAg. The peak fraction of the poly-HSA had the greatest specific activity (binding capacity per microgram of protein) for binding HBsAg.
Poly-HSA and monomeric HSA were applied in different concentrations on microtiter plates, which were subsequently used for testing different dilutions of a HBsAg-positive serum. It was found that the binding of HBsAg to the plate with poly-HSA increased with increasing amount of protein which had been used for coating the plate, up to a concentration of 50 ,ug of protein per ml of coating buffer (Fig. 2) . HBsAg was also bound to the plate coated with monomeric HSA, but to a lesser extent than to the one with poly-HSA. Furthermore, only when the highest concentration of HBsAg was tested for binding to monomeric HSA did the amount of antigen which bound to the solid phase increase with increasing concentration of coating HSA (Fig. 2) . Microtiter plates coated with dilution series of monomeric and polymerized bovine serum albumin were also tested, but no (Fig. 3a) . The binding of HBsAg to the anti-HBs solid phase of the Ausria test was not inhibited by any of the albumin solutions (Fig. 3b) Fig. 4 . Pronounced prozoning ("high-dose hook effect") was seen with the Ausria tests. The P/N values in the lower dilutions were approximately 10 times higher for PAA than for Ausria. The linear portions of the titration curves were essentially parallel in all of the comparative tests made, and the curves were linear until below a P/N of 2.1. The endpoint titers measured as P/N = 2.1 on the titration curves of HBeAg-positive and antiHBe-positive sera are plotted in Fig. 5 . By Ausria II, the geometric mean titer of HBsAg was 4-606 for the anti-HBe sera and 4-7-14 for the HBeAg samples (P < 0.01). When tested by PAA, the mean endpoint titers for the two groups of sera were 4-6.0 and 4-8-75, respectively (P < 0.01). The PAA titers covered a wider range than those for Ausria LI. Due to the parallelism of the titration curves, the titer differences between PAA and Ausria II achieved when making the comparisons at P/N levels of, for example, 10 or 20 were the same as those at P/N levels of 2.1 (except for two sera which did not reach P/N = 10 by PAA). (iv) Chimpanzee sera. Serial bleedings from the two chimpanzees infected with hepatitis B virus were tested for HBsAg by PAA and Ausria II. In the PAA, 50 ILI of a 1/10 dilution of each serum was used, and in the Ausria assay 200 [l of a 1/40 dilution of each serum was used; i.e., the same amount of serum (5 tl) was tested in the two assays. The same preparation of radiolabeled anti-HBs was used in both PAA and Ausria.
In chimp 714, HBsAg (adw) became detectable by PAA on week 16 after inoculation and remained positive until week 38 (Fig. 6) . By Ausria, HBsAg could be detected from week 19 until week 41. HBeAg was found from week 21 to week 36 in a biphasic pattern. Anti-HBe appeared during week 22 in coexistence with HBeAg and rose in titer in subsequent sera.
Chimp 755 became positive for HBsAg (ayw) by both PAA and Ausria 7 weeks after inoculation (Fig. 6) . PAA was positive until week 16, and Ausria was positive until week 14. HBeAg was found between weeks 8 and 13, and antiHBe appeared first on week 13.
Passive hemagglutination tests. The erythrocytes coated with poly-HSA were agglutinated by most sera containing HBsAg, but the titers were considerably lower than those obtained by PAA (data not shown). The cells coated with monomeric HSA also were agglutinated by HBsAg, but less frequently and to lower titers. The agglutinations of both kinds of erythrocytes could be blocked by preincubating the sera with poly-HSA but not with monomeric HSA. Bovine serum albumin-coated and uncoated control cells were not agglutinated by any of the sera tested.
DISCUSSION
The enzyme-linked immunosorbent and radioimmunoprecipitation assays, which presumably are more sensitive than the gel diffusion and passive hemagglutination tests used in previous studies (5, 8, 9) , did not detect anti-poly-HSA in any serum. It therefore is probable that the reaction between poly-HSA and HBsAg has been misinterpreted as a reaction between poly-HSA and antibodies.
Although HBsAg was shown to bind to a certain extent to microtiter plates coated with monomeric HSA (Fig. 1 and 2) , only poly-HSA could block the binding of HBsAg to solid-phase poly-HSA (Fig. 3) . Conceivably, monomeric HSA, when bound to a plastic surface, can to some extent be recognized as a polymer. The results of the blocking tests also rule out that the receptor sites on the HBsAg particles are recessed and not easily reached by single HSA molecules bound to the solid phase. (Fig. 5) . In the chimpanzees infected with hepatitis B virus, HBsAg was detected for about the same length of time by the two tests (Fig. 6 ). The higher P/N values of the PAA indicated that the poly-HSA solid phase used had capacity to bind relatively more HBsAg than the anti-HBs solid phase.
The high-dose hook effect often seen in solidphase radioimmunoassays and thought to be an effect of antibody heterogeneity of the solid phase or incomplete washing or both (12) was observed in the Ausria tests but scarcely in the PAA tests. It seems reasonable to presume that the difference between the two tests is caused by a variety of different equilibrium constants governing the anti-HBs-HBsAg reaction, in contrast to only one constant or a small number with similar values in the reaction between poly-HSA and HBsAg.
The lower reactivity with poly-HSA of HBsAg from sera with anti-HBe compared to sera containing HBeAg could be explained by relatively fewer receptor sites for poly-HSA on the HBsAg particles or by blocking of receptor sites by aggregated albumin present in the serum. That the latter mechanism in at least some cases might be of importance was supported by the fact that the HBsAg in some sera was demonstrated to lose the ability to bind to poly-HSA by storage. Thus, it seems probable that aging of sera can produce substances, such as aggregates of albumin, which can block the poly-HSA receptors of the HBsAg particles.
Whether there is any biological implication of the ability of the HBsAg to bind to poly-HSA is not known, but if structures which can be recognized as polymeric albumin are exposed on the surface of hepatocytes, they might function as receptors for the hepatitis B virus.
